Anticancer peptidylarginine deiminase (PAD) inhibitors regulate the autophagy flux and the mammalian target of rapamycin complex 1 activity

Yuji Wang, Pingxin Li, Shu Wang, Jing Hu, Xiangyun Amy Chen, Jianhui Wu, Megan Fisher, Kira Oshaben, Na Zhao, Ying Gu, Dong Wang, Gong Chen, Yanming Wang

Research output: Contribution to journalArticle

86 Citations (Scopus)

Abstract

Tumor suppressor genes are frequently silenced in cancer cells by enzymes catalyzing epigenetic histone modifications. The peptidylarginine deiminase family member PAD4 (also called PADI4) is markedly overexpressed in a majority of human cancers, suggesting that PAD4 is a putative target for cancer treatment. Here, we have generated novel PAD inhibitors with low micromolar IC50 in PAD activity and cancer cell growth inhibition. The lead compound YW3-56 alters the expression of genes controlling the cell cycle and cell death, including SESN2 that encodes an upstream inhibitor of the mammalian target of rapamycin complex 1 (mTORC1) signaling pathway. Guided by the gene expression profile analyses with YW3-56, we found that PAD4 functions as a corepressor of p53 to regulate SESN2 expression by histone citrullination in cancer cells. Consistent with the mTORC1 inhibition by SESN2, the phosphorylation of its substrates including p70S6 kinase (p70S6K) and 4E-BP1 was decreased. Furthermore, macroautophagy is perturbed after YW3-56 treatment in cancer cells. In a mouse xenograft model, YW3-56 demonstrates cancer growth inhibition activity with little if any detectable adverse effect to vital organs, whereas a combination of PAD4 and histone deacetylase inhibitors further decreases tumor growth. Taken together, our work found that PAD4 regulates the mTORC1 signaling pathway and that PAD inhibitors are potential anticancer reagents that activate tumor suppressor gene expression alone or in combination with histone deacetylase inhibitors.

Original languageEnglish (US)
Pages (from-to)25941-25953
Number of pages13
JournalJournal of Biological Chemistry
Volume287
Issue number31
DOIs
StatePublished - Jul 27 2012

Fingerprint

Autophagy
Cells
Fluxes
Tumors
Histone Deacetylase Inhibitors
Gene expression
Histones
Neoplasms
Genes
Lead compounds
Co-Repressor Proteins
Phosphorylation
Oncology
Cell growth
Cell death
Tumor Suppressor Genes
Heterografts
Phosphotransferases
Histone Code
Growth

ASJC Scopus subject areas

  • Biochemistry
  • Molecular Biology
  • Cell Biology

Cite this

Anticancer peptidylarginine deiminase (PAD) inhibitors regulate the autophagy flux and the mammalian target of rapamycin complex 1 activity. / Wang, Yuji; Li, Pingxin; Wang, Shu; Hu, Jing; Chen, Xiangyun Amy; Wu, Jianhui; Fisher, Megan; Oshaben, Kira; Zhao, Na; Gu, Ying; Wang, Dong; Chen, Gong; Wang, Yanming.

In: Journal of Biological Chemistry, Vol. 287, No. 31, 27.07.2012, p. 25941-25953.

Research output: Contribution to journalArticle

Wang, Y, Li, P, Wang, S, Hu, J, Chen, XA, Wu, J, Fisher, M, Oshaben, K, Zhao, N, Gu, Y, Wang, D, Chen, G & Wang, Y 2012, 'Anticancer peptidylarginine deiminase (PAD) inhibitors regulate the autophagy flux and the mammalian target of rapamycin complex 1 activity', Journal of Biological Chemistry, vol. 287, no. 31, pp. 25941-25953. https://doi.org/10.1074/jbc.M112.375725
Wang, Yuji ; Li, Pingxin ; Wang, Shu ; Hu, Jing ; Chen, Xiangyun Amy ; Wu, Jianhui ; Fisher, Megan ; Oshaben, Kira ; Zhao, Na ; Gu, Ying ; Wang, Dong ; Chen, Gong ; Wang, Yanming. / Anticancer peptidylarginine deiminase (PAD) inhibitors regulate the autophagy flux and the mammalian target of rapamycin complex 1 activity. In: Journal of Biological Chemistry. 2012 ; Vol. 287, No. 31. pp. 25941-25953.
@article{5dd4a746f1b1445bac17223c616cd3f9,
title = "Anticancer peptidylarginine deiminase (PAD) inhibitors regulate the autophagy flux and the mammalian target of rapamycin complex 1 activity",
abstract = "Tumor suppressor genes are frequently silenced in cancer cells by enzymes catalyzing epigenetic histone modifications. The peptidylarginine deiminase family member PAD4 (also called PADI4) is markedly overexpressed in a majority of human cancers, suggesting that PAD4 is a putative target for cancer treatment. Here, we have generated novel PAD inhibitors with low micromolar IC50 in PAD activity and cancer cell growth inhibition. The lead compound YW3-56 alters the expression of genes controlling the cell cycle and cell death, including SESN2 that encodes an upstream inhibitor of the mammalian target of rapamycin complex 1 (mTORC1) signaling pathway. Guided by the gene expression profile analyses with YW3-56, we found that PAD4 functions as a corepressor of p53 to regulate SESN2 expression by histone citrullination in cancer cells. Consistent with the mTORC1 inhibition by SESN2, the phosphorylation of its substrates including p70S6 kinase (p70S6K) and 4E-BP1 was decreased. Furthermore, macroautophagy is perturbed after YW3-56 treatment in cancer cells. In a mouse xenograft model, YW3-56 demonstrates cancer growth inhibition activity with little if any detectable adverse effect to vital organs, whereas a combination of PAD4 and histone deacetylase inhibitors further decreases tumor growth. Taken together, our work found that PAD4 regulates the mTORC1 signaling pathway and that PAD inhibitors are potential anticancer reagents that activate tumor suppressor gene expression alone or in combination with histone deacetylase inhibitors.",
author = "Yuji Wang and Pingxin Li and Shu Wang and Jing Hu and Chen, {Xiangyun Amy} and Jianhui Wu and Megan Fisher and Kira Oshaben and Na Zhao and Ying Gu and Dong Wang and Gong Chen and Yanming Wang",
year = "2012",
month = "7",
day = "27",
doi = "10.1074/jbc.M112.375725",
language = "English (US)",
volume = "287",
pages = "25941--25953",
journal = "Journal of Biological Chemistry",
issn = "0021-9258",
publisher = "American Society for Biochemistry and Molecular Biology Inc.",
number = "31",

}

TY - JOUR

T1 - Anticancer peptidylarginine deiminase (PAD) inhibitors regulate the autophagy flux and the mammalian target of rapamycin complex 1 activity

AU - Wang, Yuji

AU - Li, Pingxin

AU - Wang, Shu

AU - Hu, Jing

AU - Chen, Xiangyun Amy

AU - Wu, Jianhui

AU - Fisher, Megan

AU - Oshaben, Kira

AU - Zhao, Na

AU - Gu, Ying

AU - Wang, Dong

AU - Chen, Gong

AU - Wang, Yanming

PY - 2012/7/27

Y1 - 2012/7/27

N2 - Tumor suppressor genes are frequently silenced in cancer cells by enzymes catalyzing epigenetic histone modifications. The peptidylarginine deiminase family member PAD4 (also called PADI4) is markedly overexpressed in a majority of human cancers, suggesting that PAD4 is a putative target for cancer treatment. Here, we have generated novel PAD inhibitors with low micromolar IC50 in PAD activity and cancer cell growth inhibition. The lead compound YW3-56 alters the expression of genes controlling the cell cycle and cell death, including SESN2 that encodes an upstream inhibitor of the mammalian target of rapamycin complex 1 (mTORC1) signaling pathway. Guided by the gene expression profile analyses with YW3-56, we found that PAD4 functions as a corepressor of p53 to regulate SESN2 expression by histone citrullination in cancer cells. Consistent with the mTORC1 inhibition by SESN2, the phosphorylation of its substrates including p70S6 kinase (p70S6K) and 4E-BP1 was decreased. Furthermore, macroautophagy is perturbed after YW3-56 treatment in cancer cells. In a mouse xenograft model, YW3-56 demonstrates cancer growth inhibition activity with little if any detectable adverse effect to vital organs, whereas a combination of PAD4 and histone deacetylase inhibitors further decreases tumor growth. Taken together, our work found that PAD4 regulates the mTORC1 signaling pathway and that PAD inhibitors are potential anticancer reagents that activate tumor suppressor gene expression alone or in combination with histone deacetylase inhibitors.

AB - Tumor suppressor genes are frequently silenced in cancer cells by enzymes catalyzing epigenetic histone modifications. The peptidylarginine deiminase family member PAD4 (also called PADI4) is markedly overexpressed in a majority of human cancers, suggesting that PAD4 is a putative target for cancer treatment. Here, we have generated novel PAD inhibitors with low micromolar IC50 in PAD activity and cancer cell growth inhibition. The lead compound YW3-56 alters the expression of genes controlling the cell cycle and cell death, including SESN2 that encodes an upstream inhibitor of the mammalian target of rapamycin complex 1 (mTORC1) signaling pathway. Guided by the gene expression profile analyses with YW3-56, we found that PAD4 functions as a corepressor of p53 to regulate SESN2 expression by histone citrullination in cancer cells. Consistent with the mTORC1 inhibition by SESN2, the phosphorylation of its substrates including p70S6 kinase (p70S6K) and 4E-BP1 was decreased. Furthermore, macroautophagy is perturbed after YW3-56 treatment in cancer cells. In a mouse xenograft model, YW3-56 demonstrates cancer growth inhibition activity with little if any detectable adverse effect to vital organs, whereas a combination of PAD4 and histone deacetylase inhibitors further decreases tumor growth. Taken together, our work found that PAD4 regulates the mTORC1 signaling pathway and that PAD inhibitors are potential anticancer reagents that activate tumor suppressor gene expression alone or in combination with histone deacetylase inhibitors.

UR - http://www.scopus.com/inward/record.url?scp=84864386137&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84864386137&partnerID=8YFLogxK

U2 - 10.1074/jbc.M112.375725

DO - 10.1074/jbc.M112.375725

M3 - Article

C2 - 22605338

AN - SCOPUS:84864386137

VL - 287

SP - 25941

EP - 25953

JO - Journal of Biological Chemistry

JF - Journal of Biological Chemistry

SN - 0021-9258

IS - 31

ER -